Farnesyltransferase inhibitors

Update on Cancer Therapeutics

Volumn 1, Issue 1, 2006, Pages 17-23

  Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Farnesyltransferase; G proteins; HDJ 2; Lonafarnib; Prenylation; Ras; Rho; Tipifarnib

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMATINIB; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TAMOXIFEN; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; AFRICAN TRYPANOSOMIASIS; ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RESISTANCE; CARCINOMA; CHAGAS DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG SENSITIVITY; DYSPNEA; ESOPHAGITIS; FATIGUE; FEVER; HUMAN; HYPOKALEMIA; LEUKEMIA; LEUKOPENIA; MALARIA; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURPURA; RASH; REVIEW; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TOXICITY;

EID: 33746310371     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.05.005     Document Type: Review

References (40)

1. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 8 (1998) 49-54
2. Adjei A.A. Farnesyltransferase inhibitors. In: Schilsky R., Giaccone G., and Sondel P. (Eds). Cancer chemotherapy & biologic response modifiers (2003), Elsevier Science B.V., Amsterdam 127-144 [annual]
3. Heymach J.V., Johnson D.H., Khuri F.R., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 15 8 (2004) 1187-1193
4. Adjei A.A., Mauer A., Bruzek L., et al. Phase II study of the farnesyl transferase inhibitor r115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21 9 (2003) 1760-1766
5. Rao S., Cunningham D., de Gramont A., et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22 19 (2004) 3950-3957
6. Van Cutsem E., van de Velde H., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22 8 (2004) 1430-1438
7. Rosenberg J.E., von der Maase H., Seigne J.D., et al. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer 103 10 (2005) 2035-2041
8. Adjei A.A. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93 14 (2001) 1062-1074
9. Lebowitz P.F., Davide J.P., and Prendergast G.C. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15 (1995) 6613-6622
10. Ashar H.R., James L., Gray K., et al. FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275 (2000) 30451-30457
11. Cox A.D., and Der C.J. Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol 2 4 (2002) 388-393
12. Adjei A.A. Farnesyltransferase inhibitors. In: Giaccone G., Schilsky R., and Sondel P. (Eds). Cancer chemotherapy & biologic response modifiers (2005), Elsevier Science B.V., Amsterdam 123-133 [annual]
13. Sebti S.M., and Adjei A.A. Farnesyltransferase inhibitors. Sem Oncol 31 Suppl. 1 (2004)
14. Bayes M., Rabasseda X., and Prous J.R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 27 6 (2005) 411-461
15. Del Villar K., Urano J., Guo L., and Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem 274 (1999) 27010-27017
16. Smith V., Rowlands M.G., Barrie E., Workman P., and Kelland L.R. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 8 (2002) 2002-2009
17. Bruzek L.M., Pointer J.N., Kaufmann S.H., and Adjei A.A. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Mol Pharmacol 68 2 (2005) 477-486
18. Buzzeo R., Enkemann S., Nimmanapalli R., Alsina M., Lichtenheld M.G., Dalton W.S., et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 11 16 (2005) 6057-6064
19. Zhang B., Groffen J., and Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 106 4 (2005) 1355-1361
20. Raponi M., Belly R.T., Karp J.E., Lancet J.E., Atkins D., and Wang Y. Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer 4 (2004) 56
21. Raponi M., Lowenberg R., Lancet J.E., et al. Identification of molecular predictors of response to ZARNESTRA™ (Tipifarnib, R115777) in relapsed and refractory acute myeloid leukemia. Blood 104 (2004) 289a [abstract 861]
22. Keating A. Chronic myeloid leukemia: current therapies and the potential role of farnesyltransferase inhibitors. Semin Hematol 39 3 Suppl. 2 (2002) 11-17
23. Cortes J., Garcia-Manero G., O'Brien S., et al. A phase i study of tipifarnib in combination with imatinib mesylate (im) for patients (pts) with chronic myeloid leukemia (cml) in chronic phase (cp) who failed in therapy. Blood 104 (2004) 289a [abstract 1011]
24. Hoover R.R., Mahon F.X., Melo J.V., and Daley G.Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100 3 (2002) 1068-1071
25. Druker B.J. Overcoming resistance to imatinib by combining targeted agents. Mol Cancer Ther 2 3 (2003) 225-226
26. Cortes J., O'Brien S., Verstovsek S., et al. Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (Pts) with chronic myeloid leukemia (CML) after failure to imatinib. Blood 104 (2004) 289a [abstract 1009]
27. Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97 11 (2001) 3361-3369
28. Lancet J.E., Gotlib J., Gojo I., et al. Tipifarnib (ZARNESTRA™ in previously untreated poor-risk aml of the elderly: updated results of a multicenter phase 2 trial. Blood 104 (2004) 289a [abstract 874]
29. Kurzrock R., Fenaux P., Raza A., et al. High-risk myelodysplastic syndrome (mds): first results of international phase 2 study with oral farnesyltransferase inhibitor r115777 (ZARNESTRA™). Blood 104 (2004) 68 [abstract]
30. Johnston S.R., Hickish T., Ellis P., et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21 13 (2003) 2492-2499
31. Cloughesy T.F., Kuhn J., Robins H.I., et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 23 27 (2005) 6647-6656
32. Sun J., Blaskovich M.A., Knowles D., et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59 19 (1999) 4919-4926
33. Rossner D, Hollwitz B, Schaff C, et al. The combination of paclitaxel and the farnesyltransferase inhibitor SCH 66336 in the treatment of metastatic breast cancer. A phase I/II study. SABCS, 1068 [abstract].
34. Ellis C.A., Vos M.D., Wickline M., et al. Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 78 (2003) 59-67
35. Beeram M, Mita C, Izbicka E, et al. A phase I, pharmacokinetic, and pharmacodynamic study of the farnesyl transferase inhibitor R115777 in combination with weekly paclitaxel in patients (pts) with advanced breast cancer or other solid cancers. SABCS, 6062 [abstract].
36. Sparano JA, Vahdat L, Moulder S, Kazi A, Sebti S. Phase I-II trial of tipifarnib plus cyclophosphamide and doxorubicin in patients with metastatic and locally advanced breast cancer: clinical and molecular effects. SABCS, 1067 [abstract].
37. Dy G.K., Bruzek L.M., Croghan G.A., et al. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662 in combination with Paclitaxel and Carboplatin in patients with advanced cancer. Clin Cancer Res 11 (2005) 1877-1883
38. Buckner F.S., Eastman R.T., Yokoyama K., Gelb M.H., and Van Voorhis W.C. Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. Curr Opin Investig Drugs 6 8 (2005) 791-797
39. Buckner F.S., Eastman R.T., Nepomuceno-Silva J.L., et al. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. Mol Biochem Parasitol 122 (2002) 181-188
40. Hucke O., Gelb M.H., Verlinde C.L., et al. The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem 48 17 (2005) 5415-5418